OMEPRAZOLE Drug Patent Profile

Which patents cover Omeprazole, and what generic alternatives are available?

Omeprazole is a drug marketed by Actavis Labs Fl Inc, Apotex, Aurobindo Pharma, Breckenridge, Dr Reddys Labs Ltd, Glenmark Pharms Ltd, Hetero Labs Ltd Iii, Impax Labs, Lannett Co Inc, Lupin Ltd, Pharmobedient, Sandoz, Strides Pharma, Teva Pharms Usa, Xiromed, Zydus Pharms Usa Inc, Dexcel Pharma, Dr Reddys, Sun Pharm, Dexcel, Ajanta Pharma Ltd, Anda Repository, Aurolife Pharma Llc, Chartwell Rx, Perrigo R And D, Sciegen Pharms Inc, Strides Pharma Intl, Zydus, Zydus Pharms, Aurobindo Pharma Ltd, L Perrigo Co, Spil, Marksans Pharma, and P And L. and is included in forty-seven NDAs. There are three patents protecting this drug and one Paragraph IV challenge.

This drug has thirteen patent family members in eight countries.

The generic ingredient in OMEPRAZOLE is omeprazole magnesium. There are one hundred and thirty-one drug master file entries for this compound. Fifty-four suppliers are listed for this compound. Additional details are available on the omeprazole magnesium profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Omeprazole

A generic version of OMEPRAZOLE was approved as omeprazole magnesium by DR REDDYS LABS LTD on June 5^th, 2009.

Summary for OMEPRAZOLE

International Patents:	13
US Patents:	3
Applicants:	34
NDAs:	47
Finished Product Suppliers / Packagers:	94
Raw Ingredient (Bulk) Api Vendors:	144
Clinical Trials:	487
Patent Applications:	4,809
Drug Prices:	Drug price information for OMEPRAZOLE
Drug Sales Revenues:	Drug sales revenues for OMEPRAZOLE
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for OMEPRAZOLE
What excipients (inactive ingredients) are in OMEPRAZOLE?	OMEPRAZOLE excipients list
DailyMed Link:	OMEPRAZOLE at DailyMed

See drug prices for OMEPRAZOLE

See drug sales revenues for OMEPRAZOLE

Recent Clinical Trials for OMEPRAZOLE

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Rehman Medical Institute - RMI	PHASE4
Bristol-Myers Squibb	PHASE1
Genentech, Inc.	PHASE1

See all OMEPRAZOLE clinical trials

Pharmacology for OMEPRAZOLE

Drug Class	Proton Pump Inhibitor
Mechanism of Action	Cytochrome P450 2C19 Inhibitors Proton Pump Inhibitors

Medical Subject Heading (MeSH) Categories for OMEPRAZOLE

Anti-Ulcer Agents

Proton Pump Inhibitors

Anatomical Therapeutic Chemical (ATC) Classes for OMEPRAZOLE

A02BC	Proton pump inhibitors
A02B	DRUGS FOR PEPTIC ULCER AND GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD)
A02	DRUGS FOR ACID RELATED DISORDERS
A	Alimentary tract and metabolism

Paragraph IV (Patent) Challenges for OMEPRAZOLE

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
OMEPRAZOLE	Delayed-release Tablets	omeprazole	20 mg	022032	1	2015-06-03

US Patents and Regulatory Information for OMEPRAZOLE

OMEPRAZOLE is protected by three US patents.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Zydus Pharms	OMEPRAZOLE AND SODIUM BICARBONATE	omeprazole; sodium bicarbonate	CAPSULE;ORAL	203290-002	May 25, 2018	AB	RX	No	No
Teva Pharms Usa	OMEPRAZOLE	omeprazole	CAPSULE, DELAYED REL PELLETS;ORAL	204661-002	Jun 13, 2017		DISCN	No	No
Pharmobedient	OMEPRAZOLE	omeprazole	CAPSULE, DELAYED REL PELLETS;ORAL	205070-002	Jun 29, 2018		DISCN	No	No
Perrigo R And D	OMEPRAZOLE MAGNESIUM	omeprazole magnesium	TABLET, DELAYED RELEASE;ORAL	204152-001	Jul 30, 2015		DISCN	No	No
Dexcel Pharma	OMEPRAZOLE	omeprazole	TABLET, DELAYED RELEASE;ORAL	022032-001	Dec 4, 2007		OTC	Yes	Yes	9,023,391		Y
Aurolife Pharma Llc	OMEPRAZOLE AND SODIUM BICARBONATE	omeprazole; sodium bicarbonate	CAPSULE;ORAL	204922-002	Aug 19, 2016	AB	RX	No	No

Expired US Patents for OMEPRAZOLE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Dexcel Pharma	OMEPRAZOLE	omeprazole	TABLET, DELAYED RELEASE;ORAL	022032-001	Dec 4, 2007	9,023,391

International Patents for OMEPRAZOLE

See the table below for patents covering OMEPRAZOLE around the world.

Country	Patent Number	Title	Estimated Expiration
Austria	390119
European Patent Office	1187599	FORMULATION DE BENZIMIDAZOLE STABLE (STABLE BENZIMIDAZOLE FORMULATION)
Israel	147232	STABLE BENZIMIDAZOLE FORMULATION
World Intellectual Property Organization (WIPO)	2017216789
European Patent Office	3932396	COMPOSITIONS PHARMACEUTIQUES STABLES À DÉSINTÉGRATION ORALE (STABLE ORALLY DISINTEGRATING PHARMACEUTICAL COMPOSITIONS)
World Intellectual Property Organization (WIPO)	0078284

Supplementary Protection Certificates for OMEPRAZOLE

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0124495	SPC/GB01/006	United Kingdom		PRODUCT NAME: ESOMEPRAZOLE AS MAGNESIUM TRIHYDRATE; REGISTERED: SE 15945 20000310; SE 15946 20000310; UK PL 17901/0068-0069 20000727
0984957	SPC/GB11/013	United Kingdom		PRODUCT NAME: NAPROXEN AND ESOMEPRAZOLE; REGISTERED: UK PL 17901/0263-0001 20101105
1411900	2011/016	Ireland		PRODUCT NAME: NAPROXEN AND ESOMEPRAZOLE MODIFIED-RELEASE TABLETS; NAT REGISTRATION NO/DATE: PA0970/060/001 20101221; FIRST REGISTRATION NO/DATE: PL17901/0263-0001 20101105
1411900	SPC/GB11/015	United Kingdom		PRODUCT NAME: NAPROXEN AND ESOMEPRAZOLE; REGISTERED: UK PL 17901/0263-0001 20101105
1411900	2011C/016	Belgium		PRODUCT NAME: NAPROXENE ET ESOMEPRAZOLE (SOUS LA FORME D'ESOMEPRAZOLE MAGNESIUM TRIHYDRATE); AUTHORISATION NUMBER AND DATE: BE382505 20101214
0984957	2012/048	Ireland		PRODUCT NAME: A COMBINATION PRODUCT COMPRISING ASPIRIN AND ESOMEPRAZOLE MAGNESIUM TRIHYDRATE; NAT REGISTRATION NO/DATE: PA 970/063/001 20120831; FIRST REGISTRATION NO/DATE: 5402359; 5402367 5402375 20110812

Market Dynamics and Financial Trajectory for Omeprazole

Last updated: January 1, 2026

Executive Summary

Omeprazole, a proton pump inhibitor (PPI), remains a cornerstone in gastroenterology, predominantly prescribed for gastroesophageal reflux disease (GERD), peptic ulcers, and Zollinger-Ellison syndrome. Since its approval in the 1980s, omeprazole has evolved from a groundbreaking gastric-acid suppressor to a staple in both branded and generic formulations globally. This report analyzes current market dynamics, regulatory landscapes, competitive pressures, and future revenue trajectories, with a detailed focus on its commercial performance, innovation status, and potential growth avenues.

---

What Are the Key Market Drivers for Omeprazole?

1. Global Prevalence of Acid-Related Disorders

The rising incidence of GERD, peptic ulcers, and Helicobacter pylori infections sustains high demand for acid suppression therapies. The Global Burden of Disease Study 2019 indicated that GERD affects an estimated 20-30% of adult populations in high-income countries, with rising trends in Asia and Latin America.

2. Expanding Patient Population and Aging Demographics

Aging populations in North America, Europe, and parts of Asia increase the prevalence of acid-related diseases. The elderly, often on multiple medications, require sustained therapy, encouraging sales of both branded and generic omeprazole.

3. Affordable and Ubiquitous Generic Availability

Omeprazole's patent expiration in the early 2000s led to widespread generic manufacturing, significantly reducing costs and expanding access. In 2021, generics accounted for over 85% of global omeprazole sales, fostering high prescription volumes.

4. Proprietary Formulations and Over-the-Counter (OTC) Availability

Major markets, including the US, EU, and Japan, have OTC omeprazole formulations, further broadening consumer access and sales volume.

---

How Does the Competitive Landscape Affect Omeprazole?

Segment	Key Players	Market Share (2022)	Notes
Branded	AstraZeneca (Losec/Prilosec), AstraZeneca (Losec), Takeda (Prevacid, now less prominent)	15-20%	Decline due to generics; still relevant in certain markets
Generics	Multiple manufacturers	80-85%	Dominant segment; highly competitive price environment
OTC Market	Several OTC brands	Significant	Responsible for a substantial share, especially in mature markets

Major manufacturers include:

• Sanofi: Marketed omeprazole OTC in Europe and US under Prilosec OTC.
• Takeda Pharmaceutical: Marketed initial formulations, now focusing on other PPIs.
• Synthesis of generics: Numerous local manufacturers in emerging markets.

Patent and Regulatory Influences

No patent challenges currently threaten omeprazole as of 2023, with the original patents long expired. However, innovative formulations that improve bioavailability or reduce side effects now command niche markets.

---

What Is the Regulatory Landscape Shaping Omeprazole’s Market?

1. Patent Expirations and Generic Approval Policies

Most patents expired by 2010-2012, leading to a surge in generics. Regulatory agencies like the FDA, EMA, and PMDA have streamlined approval pathways for generics, further intensifying competition.

2. OTC Switches and Over-the-Counter Market Expansion

Authorities have approved OTC formulations to meet consumer demand, notably:

• FDA (2014): Approved OTC Prilosec for 20mg for short-term use.
• EMA (2011): Allowed OTC omeprazole formulations in European countries.

3. Potential Future Restrictions

Recent safety concerns regarding long-term PPI use, such as increased risk of renal disease, osteoporosis, and infections, have prompted regulatory reviews, potentially leading to more stringent labeling or usage guidelines [1].

---

What Are the Financial Trends and Projections?

1. Historical Revenue Performance

Year	Global Sales (USD billion)	Key Notes
2010	$4.2	High generic penetration post-patent expiry
2015	$4.8	Growth driven by OTC sales, emerging markets
2020	$4.5	Slight decline due to safety concerns, new competitors

2. Current Market Value (2022)

• Estimated global sales: USD 4.6 billion.
• Major markets: North America (45%), Europe (25%), Asia-Pacific (20%), rest of the world (10%).

3. Forecast for 2025 and 2030

Year	Predicted Sales (USD billion)	Growth Rate (CAGR)	Underlying Factors
2025	$5.2 - $5.8	4-6%	Market maturation, OTC growth, new markets
2030	$6.0 - $7.2	5-7%	Aging populations, expanded OTC availability

4. Revenue Breakdown

Segment	Percentage of 2022 Revenue	Remarks
Prescription (Rx)	50%	Higher margins, controlled markets
Over-the-Counter (OTC)	30%	Volume-driven, tax-efficient
Generics (Bulk sales)	20%	Price competition dominates

---

How Is Innovation Shaping Omeprazole’s Future?

1. New Formulations and Delivery Modes

• DR (Delayed Release) and ER (Extended Release): Improve pharmacokinetics and patient compliance.
• Combination Therapies: Omeprazole + antibiotics for H. pylori eradication.
• Novel Delivery: Liposomal or nanoparticle-based formulations aimed at reducing dosing frequency.

2. Pharmacogenomics and Personalized Medicine

Genetic markers influencing PPI metabolism (e.g., CYP2C19 polymorphisms) are increasingly being integrated into therapy selection, possibly impacting market share due to tailored treatments.

3. Potential Biosimilars and Biobetters

While biosimilars are not applicable for small-molecule drugs like omeprazole, innovative analogs that offer superior safety or efficacy could disrupt existing products.

---

How Do Regional Differences Impact Market Dynamics?

Region	Market Characteristics	Key Drivers	Challenges
North America	Mature, high OTC penetration, safety concerns influencing sales	Aging population, OTC availability	Regulatory scrutiny, patent issues
Europe	Strong OTC sector, high generic penetration	Healthcare policies, consumer awareness	Price competition, regulatory changes
Asia-Pacific	Rapid growth, expanding middle class, emerging markets	Growing GERD prevalence, urbanization	Regulatory heterogeneity, pricing pressures
Latin America	Increasing access, lower per capita consumption	Epidemiological shift, healthcare reforms	Limited infrastructure, market fragmentation

---

FAQs on Omeprazole Market Dynamics and Financials

Q1: What are the primary factors limiting future revenue growth for omeprazole?
A1: Growing safety concerns with long-term PPI use, market saturation in developed countries, and intense pricing competition among generics constrain further revenue expansion.

Q2: How does OTC availability influence omeprazole’s market?
A2: OTC sales significantly boost volume, especially in mature markets, while also reducing prescription dependence, but may limit the potential for premium pricing.

Q3: Are there new competitors or innovations threatening omeprazole’s market position?
A3: Yes, newer PPIs and alternative treatments, such as potassium-competitive acid blockers (e.g., vonoprazan), could erode market share if they demonstrate superior safety or efficacy.

Q4: What’s the outlook for branded versus generic omeprazole sales?
Q4: Generic formulations dominate in volume, but branded products retain a niche in specific markets, often emphasizing superior formulation, safety data, or pediatric approvals.

Q5: What role do emerging markets play in future omeprazole sales?
A5: Rapid economic development and increasing disease burden create significant growth opportunities, making emerging markets critical for sustained revenue growth.

---

Key Takeaways

Insight	Implication for Stakeholders
Market maturity in developed economies limits high growth; emerging markets drive future expansion.	Invest in expanding distribution channels and formulating region-specific strategies.
OTC sales dominate in mature markets, reducing prescription volumes but increasing access.	Focus on consumer education and regulatory navigation for OTC formulations.
Safety concerns and regulatory scrutiny could lead to shifts in prescribing patterns.	Prioritize post-marketing safety and pharmacovigilance initiatives.
Innovation in formulations and personalized medicine may carve out niche markets.	Invest in R&D and strategic partnerships targeting advanced delivery systems.
Competitive pressures from generics and alternative therapies necessitate cost-competitiveness.	Optimize manufacturing efficiency and diversify portfolio offerings.

---

References

[1] Katz, P.O. et al. (2021). Long-term safety of proton pump inhibitors: A review of the evidence. Gastroenterology, 160(7), 2194-2203.